Ellis P A, Colls B M
Oncology Service, Christchurch Hospital, New Zealand.
Hematol Oncol. 1992 May-Aug;10(3-4):207-11. doi: 10.1002/hon.2900100311.
Eleven patients with solitary plasmacytoma of bone were seen between 1978 and 1991. A retrospective review of the clinical features, treatment and survival of these patients was made with the aim of helping to define those at risk for early development of myeloma. Nine patients (82 per cent) had paraparoteinemia at diagnosis. Treatment consisted of local irradiation plus or minus surgery (nine patients) and surgery alone (two patients). No patient received adjuvant chemotherapy. One patient had evidence of both generalized osteopenia and immunoparesis, and progressed to myeloma within six months. Four patients (36 per cent) progressed to myeloma. All of these had paraprotein levels which continued to rise following initial treatment. Three patients died of myeloma at 12, 81 and 144 months and the other patient is alive with myeloma at 76 months. Patients without paraproteinemia at presentation or whose paraprotein decreased after treatment did not progress to myeloma. Three patients have been followed for 8, 11 and 19 years with no evidence of myeloma. Failure of paraprotein to clear after local treatment suggests occult disseminated disease and is predictive of later development of overt myeloma.
1978年至1991年间共诊治了11例骨孤立性浆细胞瘤患者。对这些患者的临床特征、治疗及生存情况进行了回顾性分析,旨在明确哪些患者有早期发展为骨髓瘤的风险。9例患者(82%)在诊断时有副蛋白血症。治疗包括局部放疗加或不加手术(9例)以及单纯手术(2例)。无一例患者接受辅助化疗。1例患者有全身骨质减少和免疫球蛋白缺乏的证据,在6个月内进展为骨髓瘤。4例患者(36%)进展为骨髓瘤。所有这些患者的副蛋白水平在初始治疗后持续升高。3例患者分别在12个月、81个月和144个月死于骨髓瘤,另1例患者在76个月时患骨髓瘤存活。就诊时无副蛋白血症或治疗后副蛋白水平下降的患者未进展为骨髓瘤。3例患者已分别随访8年、11年和19年,无骨髓瘤证据。局部治疗后副蛋白未能清除提示存在隐匿性播散性疾病,并预示后期会发展为明显的骨髓瘤。